Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sonoma Pharmaceuticals Inc SNOA

Healthcare
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar... see more

Recent & Breaking News (NDAQ:SNOA)

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Accesswire 10 days ago

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Accesswire November 11, 2024

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Accesswire November 7, 2024

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Accesswire October 31, 2024

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Accesswire October 22, 2024

Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences

Accesswire October 21, 2024

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Accesswire September 19, 2024

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Accesswire September 17, 2024

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Accesswire September 11, 2024

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Accesswire August 28, 2024

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff

Accesswire August 26, 2024

Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

Accesswire August 21, 2024

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results

Accesswire August 8, 2024

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine

Accesswire July 9, 2024

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

Accesswire June 17, 2024

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Accesswire May 9, 2024

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

Accesswire April 9, 2024

Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

Accesswire April 4, 2024

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

Accesswire March 28, 2024

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Accesswire March 27, 2024